Stella Pharma (4888) Fundamentals 2026 — Revenue Analysis | SniperIQ
Stella Pharma (4888) is a JP-listed Healthcare company in Biotechnology with a market capitalization of ¥11.1B, trading at ¥308.00 on the JPX. This SniperIQ fundamentals page covers Stella Pharma's valuation, profitability (net margin -241.5%), revenue (¥323M in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Stella Pharma's market cap?
Stella Pharma (4888) has a market capitalization of approximately ¥11.1B, trading at ¥308.00 on the JPX. Market cap moves with the live share price.
What is Stella Pharma's P/E ratio?
Stella Pharma's trailing twelve-month P/E ratio is not meaningful (negative or nil earnings), with a price-to-book (P/B) of 4.3x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Stella Pharma?
Stella Pharma runs a net profit margin of -241.5%, a gross margin of 81.9%, and an operating margin of -233.8%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Stella Pharma generate?
Stella Pharma reported revenue of ¥323M for fiscal year 2025, with net income of -¥781M and earnings per share (EPS) of -22.95. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Stella Pharma pay a dividend?
Stella Pharma does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.
Is Stella Pharma financially healthy?
Stella Pharma carries a debt-to-equity ratio of 0.31x and a current ratio of 16.75x, with a market beta of 0.28. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Stella Pharma a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Stella Pharma (4888) the key facts are: market cap ¥11.1B, revenue ¥323M, 52-week range 200-995. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track Stella Pharma's full fundamentals live
Get Stella Pharma's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.